Belimumab for lung scarring in autoimmune disease
Treatments studied
Part of Immune system & allergy, Lungs & breathing, Skin clinical trials.
This study tests whether a drug called belimumab can help people with lung scarring caused by certain autoimmune diseases (like rheumatoid arthritis or lupus). If you have active lung disease despite standard therapy, this trial may be an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a connective tissue disease like rheumatoid arthritis, lupus, or myositis with lung scarring (ILD).
- Your lung disease is still active or getting worse despite standard treatments.
- You are not on continuous oxygen, and your lung function is not severely low.
- You are not pregnant, and if you could become pregnant, you agree to use highly effective birth control.
- You are willing to give yourself (or have a caregiver give) the study drug as a shot under the skin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an observational (non-treatment) study that collects information about how interstitial lung disease (lung scarring) happens in people with certain autoimmune or immune-related conditions. It uses patient interviews or existing medical records to better understand the pattern and causes, which may help future care.
This study tests the long-term safety and effectiveness of belimumab for people with lung scarring caused by scleroderma or other connective tissue diseases. It is for patients who already completed a one-year study with belimumab and were not considered treatment failures.
This trial tests efzofitimod to see if it can improve or slow lung disease caused by systemic sclerosis (scleroderma), and to check safety and side effects. It focuses on people with relatively early disease and measurable lung involvement on lung scans.
This Phase 2/3 study tests whether belimumab can improve outcomes and safety in adults with systemic sclerosis (scleroderma) that has caused lung scarring. It may help by reducing active or worsening immune-driven disease in the lungs.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This study looks at how well belimumab works in people with systemic lupus erythematosus (SLE), a condition where the immune system attacks the body. It aims to see if the treatment helps, regardless of how well it worked in the past.
Hear when a new Lung Diseases, Interstitial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.